Kinetic gate: high-efficiency LNP platform for CNS & hepatic delivery (34.2% endosomal escape)

What it is & Why it matters: Kinetic Gate Therapeutics Ltd has developed a modular Lipid Nanoparticle (LNP) architecture designed to solve the two greatest failures in genetic medicine: crossing the Blood-Brain Barrier (BBB) and overcoming endosomal entrapment. Our CNS-1 and LIV-1 platforms provide a "size-locked" delivery vehicle for mRNA, siRNA, and small molecules, targeting neurodegenerative and autoimmune diseases with unprecedented precision.

How it works: Using high-fidelity Martini 3.0 Coarse-Grained simulations, we engineered a 90nm spherical morphology optimized for active Receptor-Mediated Transcytosis (RMT). The system utilizes a proprietary "shield-and-strike" surface modification that stabilizes the particle during circulation but triggers rapid release upon cellular entry.

Proof to date: Our computational validation demonstrates a 34.2% Endosomal Escape efficiency, a significant leap over current industry standards. Furthermore, the architecture is optimized for clinical scalability with a validated 18 mL/min Total Flow Rate (TFR) in microfluidic environments. We currently hold UK Patent Applications (GB2606071.5 and GB2607317.1) covering the platform and its inverse vaccine applications.